Wells Fargo analyst Derek Archila raised the firm’s price target on Cabaletta Bio to $14 from $4 and keeps an Overweight rating on the shares. The analyst likes the risk/reward ahead of the DSG3-CAART + cyclophos + IVIG updates in 2023. The stock could double if meaningful activity on autoAbs and efficacy measures is seen.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CABA: